Elevation Oncology (ELEV) Insider Trading & Ownership $0.59 +0.01 (+1.45%) (As of 10:39 AM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Elevation Oncology (NASDAQ:ELEV) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.10%Number OfInsiders Buying(Last 3 Years)0Number OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$2.90 M Get ELEV Insider Trade Alerts Want to know when executives and insiders are buying or selling Elevation Oncology stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ELEV Insider Buying and Selling by Quarter Ad Angel PublishingTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Elevation Oncology Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/25/2022Global Strategic Fund I VenbioMajor ShareholderSell702,737$4.12$2,895,276.44 (Data available from 1/1/2013 forward) ELEV Insider Trading Activity - Frequently Asked Questions Who is on Elevation Oncology's Insider Roster? The list of insiders at Elevation Oncology includes Global Strategic Fund I Venbio. Learn more on insiders at ELEV. What percentage of Elevation Oncology stock is owned by insiders? 8.10% of Elevation Oncology stock is owned by insiders. Learn more on ELEV's insider holdings. Elevation Oncology Key ExecutivesMr. Joseph J. Ferra Jr. (Age 49)CEO, President & Director Compensation: $897.28kDr. David Dornan Ph.D. (Age 46)Chief Scientific Officer Compensation: $620.92kMs. Valerie Malyvanh Jansen M.D. (Age 46)Ph.D., Chief Medical Officer Compensation: $685.94kMs. Tammy Furlong CPA (Age 53)P.M.P., CFO & Secretary Mr. Ryan BloomerHead of Tech OpsCandice MasseSenior Director of Corporate Communications & Investor RelationsMr. Robert C. YangVice President of Legal AffairsMr. Biren ShahSenior Vice President of Business & Corporate Development More Insider Trading Tools from MarketBeat Related Companies SCYNEXIS Insider Transactions Bolt Biotherapeutics Insider Transactions Bright Minds Biosciences Insider Transactions Seres Therapeutics Insider Transactions Sagimet Biosciences Insider Transactions Black Diamond Therapeutics Insider Transactions Candel Therapeutics Insider Transactions Skye Bioscience Insider Transactions Cardiff Oncology Insider Transactions Adverum Biotechnologies Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:ELEV) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevation Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
